Clinical Trial Update: CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease [Phase 2]

View source ↗

Summary

Phase 2 trial comparing CPX-351 to immediate stem cell transplantation for high-grade myeloid cancers with measurable residual disease was terminated; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts-2
• Myeloid Neoplasm

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Status: TERMINATED | Results posted: 2024-05-23